Review for 10.1186/s12876-016-0516-2 (2016)

Reviewer ’s report  
 
Title: Prevalence of Hepatitis B and Clinical Outcomes in Inflammatory Bowel Disease Patients 
in a Viral -endemic Region  
 
 
Version: 1 Date: 13 May 2016  
 
 
Reviewer: Cyrla  Zaltman  
 
Reviewer's report:  
 
Some suggestions must be considered before the acceptance:  
 
1) Any others IBD -associated liver disease, as primary sclerosing must be a exclusion criteria, a s 
it could a confounder factor and occurs just in one patient in your cohort  
 
2) the sentence -  All patients were tested negative for hepatitis A and hepatitis C - must be 
included in the methodology , not in the results  
 
3) The legend of table 2 -  Univari ate and multivariate analysis of determinants of liver 
dysfunction   , must  be  changed to elevated or altered transaminases  
 
4) A revision of the text by an english medical reviewer  is necessary, as there are  many 
repetitions of unnecessary words , and long sentences.numerous errors of English language 
usage.  
 
All others comments made by the reviewers  were met  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supporte d by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please spe cify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Needs some language corrections before being published  
 
Declaration of competing interests  
Please comp lete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from 
an organisation that may in any way gain or lose financially from the publication of t his 
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently apply ing for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is y es to any, please give details below.  
 
I declare that I have no competing interests' below.  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand th at any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal